

Bulletin from Extraordinary General Meeting in BICO Group AB (publ)

The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of BICO Group AB (publ) (“BICO” or the “Company”) held today on 14 December 2022.

Adoption of a long-term incentive programme

The EGM resolved, in accordance with the Board of Directors’ proposal, to adopt a long-term incentive programme (**Co-worker LTIP 2022**) directed at employees within the BICO group. The rationale behind the incentive programme is, among other things, to contribute to higher motivation and commitment among the employees and to retain knowledgeable and experienced employees. Co-worker LTIP 2022 is a programme under which the employees, free of charge, will be granted a right to receive warrants depending on the Company’s fulfilment of certain performance requirements (see below) and will be subject to a three and a half-year vesting period. Co-worker LTIP 2022 will comprise of current employees (a total of approximately 900 individuals), and participants who may be employed within the BICO group in the foreseeable future. In order to enable the incentive programme, the EGM also resolved on an issue of not more than 2,500,000 warrants directed at the wholly owned subsidiary BICO International AB. Based on the existing number of shares in the Company, Co-worker LTIP 2022, upon exercise of all 2,500,000 warrants, means that the share capital may increase by a maximum of SEK 62,500 and a maximum dilution corresponding to approximately 3.75 per cent of the outstanding share capital and votes in the Company.

For further information, please contact:

Carsten Brovall, Chairman of the Board of Directors, BICO Group AB

Email: cb@bico.com

Åsa Hillsten, Interim SVP & Head of Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

The information was submitted for publication, through the agency of the contact persons set out above, on 14 December 2022, at 15.00 CET.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Large-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[Bulletin from Extraordinary General Meeting in BICO Group AB \(publ\)](#)